Business Development (7)

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...

Challenge: A company developing a portfolio of therapeutic cannabinoids for neurological conditions was seeking a stock exchange listing and asked Alacrita to develop documentation supporting its...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge: A biotech company developing small molecule drugs for oncology was in the process of licensing negotiations with a pharma company for its lead asset. The asset, set to enter the clinic in...

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....

Challenge: In order to better review potential acquisition and licensing opportunities, a pharma company asked Alacrita to landscape the companies, medical devices, digital technologies, research...

Challenge: A clinical stage biotech company developing novel oncology treatments was planning a private funding round to progress the clinical development of its lead product. The biotech requested...

Challenge: An oncology biotech company with a proprietary therapeutics development platform technology was in the process of fundraising activities. The company's pipeline included three main...

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...

Challenge: A pharmaceutical company with marketed therapeutics in several respiratory disorders wanted to supplement its internal pipeline with external innovation. The company had already searched...

Challenge: A UK-based VC wished to invest in a biotech spin-out focussed on the development of R&D tools using induced pluripotent stem cells (iPSCs) as organoids to mimic human tissues. These...

Challenge: Following a pre-due diligence exercise, an investment firm asked Alacrita to conduct a deeper due diligence on a biotech company's vaccine platform technology targeted towards infectious...